ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Genmab AS

Genmab AS (GMAB)

24.14
0.43
(1.81%)
Cerrado 08 Marzo 3:00PM
24.20
0.06
(0.25%)
Fuera de horario: 6:59PM
Gráfico avanzado

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
24.20
Postura de Compra
23.32
Postura de Venta
24.57
Volume Operado de la Acción
803,348
24.00 Rango del Día 24.325
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
Precio Anterior
23.71
Precio de Apertura
24.04
Última hora de negociación
Volumen financiero
US$ 19,416,397
Precio Promedio Ponderado
24.1693
Volumen promedio (3 m)
-
Acciones en circulación
661,871,860
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
20.25
Beneficio por acción (BPA)
11.85
turnover
21.53B
Beneficio neto
7.84B

Acerca de Genmab AS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the stan... Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biogenetic (human)
Sitio web
Sede
Copenhagen, Dnk
Fundado
2000
Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GMAB. The last closing price for Genmab AS was US$23.71. Over the last year, Genmab AS shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Genmab AS currently has 661,871,860 shares in issue. The market capitalisation of Genmab AS is US$15.69 billion. Genmab AS has a price to earnings ratio (PE ratio) of 20.25.

GMAB Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

GMAB - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Genmab AS?
El precio actual de las acciones de Genmab AS es US$ 24.20
¿Cuántas acciones de Genmab AS están en circulación?
Genmab AS tiene 661,871,860 acciones en circulación
¿Cuál es la capitalización de mercado de Genmab AS?
La capitalización de mercado de Genmab AS es USD 15.69B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Genmab AS?
Genmab AS ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Genmab AS?
El ratio precio/beneficio de Genmab AS es 20.25
¿Cuál es el ratio de efectivo a ventas de Genmab AS?
El ratio de efectivo a ventas de Genmab AS es 7.38
¿Cuál es la moneda de reporte de Genmab AS?
Genmab AS presenta sus resultados financieros en DKK
¿Cuál es el último ingresos anual de Genmab AS?
El último ingresos anual de Genmab AS es DKK 21.53B
¿Cuál es el último beneficio anual de Genmab AS?
El último beneficio anual de Genmab AS es DKK 7.84B
¿Cuál es la dirección registrada de Genmab AS?
La dirección registrada de Genmab AS es KALVEBOD BRYGGE 43, COPENHAGEN, 1260
¿Cuál es la dirección del sitio web de Genmab AS?
La dirección del sitio web de Genmab AS es www.genmab.com
¿En qué sector industrial opera Genmab AS?
Genmab AS opera en el sector BIOGENETIC (HUMAN)

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CAPSCapstone Holding Corp
US$ 3.50
(1,300.00%)
36.33k
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.13M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
476.73M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
618.03M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.77M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
618.03M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
476.73M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
333.91M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
140.23M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
140.05M

GMAB Finanzas

Finanzas

GMAB Discussion

Ver más
XenaLives XenaLives 5 años hace

Products in development
Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.


http://www.genmab.com/product-pipeline/products-in-development
👍️0
XenaLives XenaLives 5 años hace

Product pipeline
Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and is developing a clinical pipeline of antibody therapeutics for the treatment of cancer.


http://www.genmab.com/product-pipeline

👍️0
XenaLives XenaLives 5 años hace

About Genmab A/S
Genmab A/S operates as a biotechnology company. The Company specializes in development of antibody therapeutics for the treatment of cancer. Genmab serves customers worldwide.


ADDRESS
Kalvebod Brygge 43 Copenhagen V, 1560 Denmark
PHONE
45-7020-2728
WEBSITE
www.genmab.com






https://www.bloomberg.com/quote/GMXAY:US
👍️0
XenaLives XenaLives 5 años hace
GMXAY largest holding in Blackrock fund:

iShares Genomics Immunology and Healthcare ETF


https://www.blackrock.com/us/individual/products/308878/
👍️0
PennyStock Alert PennyStock Alert 5 años hace
Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-063632870.html
👍️0
TenKay TenKay 7 años hace
GMXAY Forward Split 5 for 1 effective May 1, 2018

http://otce.finra.org/DailyList
👍️0
trendmkr trendmkr 9 años hace
Here are Two Biotech Stocks to Watch in January - article mentions Genmab

http://marketexclusive.com/here-are-two-biotech-stocks-to-watch-in-january/1228/
👍️0
stocktrademan stocktrademan 10 años hace
$GMXAY DD Notes ~ http://www.ddnotesmaker.com/GMXAY

bullish

$GMXAY recent news/filings

## source: finance.yahoo.com

Thu, 04 Dec 2014 06:36:32 GMT ~ Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-063632870.html
*********************************************************

Mon, 24 Nov 2014 13:53:34 GMT ~ Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-135334071.html
*********************************************************

Mon, 10 Nov 2014 08:17:15 GMT ~ Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-iii-combination-081715458.html
*********************************************************

Thu, 06 Nov 2014 14:40:06 GMT ~ Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)

[GlobeNewswire] - Media Release

read full: http://finance.yahoo.com/news/genmab-announces-daratumumab-ofatumumab-data-144006800.html
*********************************************************

Thu, 06 Nov 2014 14:10:48 GMT ~ Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL

[GlobeNewswire] - COPENHAGEN, Denmark -- Genmab A/S (OMX: GEN) announced today additional data from the interim analysis of the ofatumumab (Arzerra(tm)) Phase III study, PROLONG (OMB112517). The study evaluated ofatumumab ...

read full: http://finance.yahoo.com/news/genmab-announces-additional-data-phase-141048186.html
*********************************************************


$GMXAY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$GMXAY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/GMXAY/company-info
Ticker: $GMXAY
OTC Market Place: OTC Pink Current
CIK code: 0001434265
Company name: Genmab A/S
Company website: http://www.genmab.com
Incorporated In: Denmark

Business Description: Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.


$GMXAY share structure

## source: otcmarkets.com

Market Value: $2,578,167,309 a/o Dec 03, 2014
Shares Outstanding: 51,052,818 a/o Jul 30, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$GMXAY extra dd links

Company name: Genmab A/S
Company website: http://www.genmab.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GMXAY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GMXAY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GMXAY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/news - http://finance.yahoo.com/q/h?s=GMXAY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GMXAY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GMXAY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GMXAY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Genmab+A%2FS&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Genmab+A%2FS
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Genmab+A%2FS&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.genmab.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.genmab.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.genmab.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GMXAY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001434265&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GMXAY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GMXAY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GMXAY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GMXAY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GMXAY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GMXAY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GMXAY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GMXAY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GMXAY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GMXAY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GMXAY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GMXAY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GMXAY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GMXAY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GMXAY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GMXAY



$GMXAY DD Notes ~ http://www.ddnotesmaker.com/GMXAY
👍️0
akademikeren akademikeren 11 años hace
Genmab has taken a beating along with a lot of american Biotech. It is poised for a lot of news starting the 19th of april with a PDUFA date on their submission on 1st line CLL drug Arzerra. For those of you unfamiliar with this Company I will be posting news regularly and tell you something about the history.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock